Mucopolysaccharidosis Type I (MPS I) is a rare metabolic disorder that impedes the breakdown of glycosaminoglycans (GAGs), leading to their accumulation in tissues and organs. This buildup causes progressive damage, with symptoms such as developmental delays, organ enlargement, and skeletal issues. Despite the market's small size, MPS I therapeutics are vital for improving the lives of affected...